A Phase I, open-label study to determine the maximum tolerated dose (MTD) and to evaluate the safety profile of CC-4047 [pomalidomide] in subjects with advanced solid tumours.
Phase of Trial: Phase I
Latest Information Update: 27 Aug 2012
At a glance
- Drugs Pomalidomide (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2011 Planned End Date changed from 1 Apr 2011 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 11 Jan 2011 Planned end date changed from 1 Apr 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.